S-Carboxymethylcysteine inhibits adherence of *Streptococcus pneumoniae* to human alveolar epithelial cells

Tomoko Sumitomo,† Masanobu Nakata,† Masaya Yamaguchi,‡ Yutaka Terao† and Shigetada Kawabata†

†Department of Oral and Molecular Microbiology, Osaka University Graduate School of Dentistry, Osaka, Japan
‡Department of Cell Membrane Biology, Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan


**INTRODUCTION**

*Streptococcus pneumoniae* is a major pathogen of respiratory infections that utilizes platelet-activating factor receptor (PAFR) for firm adherence to host cells. The mucolytic agent S-carboxymethylcysteine (S-CMC) has been shown to exert inhibitory effects against infection by several respiratory pathogens including *S. pneumoniae* in vitro and in vivo. Moreover, clinical studies have implicated the benefits of S-CMC in preventing exacerbation of chronic obstructive pulmonary disease, which is considered to be related to respiratory infections. In this study, to assess whether the potency of S-CMC is attributable to inhibition of pneumococcal adherence to host cells, an alveolar epithelial cell line stimulated with interleukin-1α was used as a model of inflamed epithelial cells. Despite upregulation of PAFR by inflammatory activation, treatment with S-CMC efficiently inhibited pneumococcal adherence to host epithelial cells. In order to gain insight into the inhibitory mechanism, the effects of S-CMC on PAFR expression were also investigated. Following treatment with S-CMC, PAFR expression was reduced at both mRNA and post-transcriptional levels. Interestingly, S-CMC was also effective in inhibiting pneumococcal adherence to cells transfected with PAFR small interfering RNAs. These results indicate S-CMC as a probable inhibitor targeting numerous epithelial receptors that interact with *S. pneumoniae*.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; DAPI, 4,6-diamidino-2-phenylindole; GSH, glutathione; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; NF-κB, nuclear factor-κB; PAFR, platelet-activating factor receptor; plgR, polymeric immunoglobulin receptor; S-CMC, S-carboxymethylcysteine; siRNA, small interfering RNA.

Supplementary data are available with the online version of this paper.
chronically inflamed airways. In fact, activation of airway epithelial cells with inflammatory cytokines results in upregulation of PAFR, which in turn facilitates efficient pneumococcal adherence to epithelial cells (Cundell et al., 1995; Ishizuka et al., 2003). To gain insight into this mechanism, we examined whether S-CMC inhibited pneumococcal adherence mediated by phosphorylcholine and PAFR.

**METHODS**

**Pneumococcal strains and growth conditions.** *S. pneumoniae* serotype 6B strains P-03-90, P-03-160 and P-03-200, and serotype 19F strains P-03-11, P-03-99 and P-03-163, were isolated from sputum samples from patients with pneumonia. The pneumococcal strains were grown in tryptic soy broth (Becton Dickinson) until the late-exponential phase (OD₆₀₀ of 0.6). The cells were then harvested, washed twice with PBS, and resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Wako) supplemented with 10% fetal bovine serum (SAFC Biosciences).

**Cell culture.** The human alveolar carcinoma cell line A549 (RIKEN Cell Bank) derived from type II pneumocytes was maintained in DMEM supplemented with 10% fetal bovine serum at 37 °C in a 5% CO₂ atmosphere.

**Adherence assay.** Adherence assays were performed as described previously (Yamaguchi et al., 2008), with minor modifications. Briefly, A549 cells were cultured in 24-well plates at a density of 2 × 10⁵ cells per well and infected with 2 × 10⁶ c.f.u. bacteria (m.o.i. of 10) for 1 h. For quantification of bacterial adherence, infected cells were washed with PBS and lysed with distilled water. Serial dilutions of the lysates were plated on tryptic soy agar plates to determine the number of c.f.u.

**Treatment of epithelial cells with S-CMC.** For adherence inhibition assays, A549 cells were treated with various concentrations (100, 10, 1, 0.1, 0.01 and 0.001 μg ml⁻¹) of S-CMC (Kyorin Pharmaceuticals) and incubated at 37 °C for 30 min in a 5% CO₂ atmosphere, after which the cells were washed three times with PBS. Control cells were prepared in a similar manner except that they were not treated with S-CMC. The effect of S-CMC on the viability of bacteria and A549 cells was assessed by a plate counting method and trypan blue exclusion assay, respectively.

**Immunoblotting.** A549 cells were seeded at a density of 2 × 10⁵ cells per well onto cover slides pretreated with poly-l-lysine (13 mm diameter; Matsumani) and cultured for 24 h at 37 °C in a 5% CO₂ atmosphere. The cells were treated with S-CMC, followed by stimulation with IL-1ß and then infected with *S. pneumoniae* strain P-03-11 at an m.o.i. of 10 for 1 h and fixed with 4% paraformaldehyde in PBS for 20 min at room temperature. Finally, the cells were blocked with 5% BSA in PBS. To observe the localization of *S. pneumoniae* on the epithelial cells, the bacterial cells were visualized with rabbit polyclonal antiserum raised against the serotype 19 capsule (Denka Seiken) and Alexa Fluor 488-conjugated anti-rabbit IgG (Molecular Probe). Infected cells were reacted with a primary rabbit polyclonal antibody targeting the human PAFR (Cayman), followed by incubation with Alexa Fluor 594-conjugated anti-rabbit IgG (Molecular Probe). Cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Finally, the cover slides were mounted onto glass slides using VECTASHIELD mounting medium (Vector) and examined using an LSM 510 confocal microscope system, version 3.2 (Carl Zeiss). Images were obtained and processed with LSM 510 software.

**RNA interference.** Pre-designed ON-TARGETplus SMARTpool small interfering RNAs (siRNAs) against human PAFR and negative controls were purchased from ThermoScientific and Life Technologies, respectively. A549 cells were transfected with four siRNA duplexes targeting different regions of the PAFR gene at a final concentration of 50 nM. Transfection of siRNA was carried out as reported previously (Sumitomo et al., 2011).

**Qualitative analysis of capsule production.** Analysis of capsule production was carried out by ELISA. *S. pneumoniae* strains were grown to exponential phase (OD₆⁰₀=0.4) and centrifuged at 7000 g for 5 min. Pelleted cells were resuspended in PBS, Polystyrene plates (Iwaki) were coated with the bacterial suspension and air-dried overnight. The plates were blocked with PBS containing 0.004% Block Ace, followed by incubation with a primary rabbit polyclonal antibody against the serotype 6 capsule or serotype 19 capsule for 1 h at room temperature. The plates were then washed with PBS and incubated with horseradish peroxidase-conjugated secondary antibody (Cell Signalling) for 1 h at room temperature. Following the washing steps, the reaction was developed with TMB peroxidase substrate (Moss). The reactions were stopped with 0.5 M sulfuric acid and the A₄₅₀ was measured.

**Statistical analysis.** A Kruskal–Wallis test was used to determine whether any of the groups exhibited a statistically significant difference with regard to the percentage of pneumococcal adherence. If the Kruskal–Wallis test results demonstrated at least one of the
groups to be statistically different, post-hoc analysis using a Mann–Whitney U test with Bonferroni correction was used to adjust the significance value (P). Simple paired comparisons were performed using a Mann–Whitney U test. A confidence interval with a P value of <0.05 was considered to be significant.

RESULTS AND DISCUSSION

It has been reported that S-CMC is effective in preventing pneumococcal adherence to human pharyngeal epithelial cells (Cakan et al., 2003; Suer et al., 2008). As the serotype 6B and 19F strains have been reported to be major causes of pneumococcal infection throughout the world (Chiba et al., 2005; Henriques-Normark et al., 2008), we first investigated whether S-CMC also inhibited adherence of these types of clinical isolates to the alveolar epithelial cell line A549 (Fig. 1). Utilizing three strains for each serotype and S-CMC at concentrations of 0.001–100 μg ml⁻¹, adherence assays were conducted. S-CMC reduced the adherence of these six strains to A549 cells in a dose-dependent manner. In particular, treatment of A549 cells with S-CMC at concentrations of 10 and 100 μg ml⁻¹ resulted in a significant decrease in the adherence of all tested strains compared with untreated cells. In contrast, treatment with 100 μg S-CMC ml⁻¹ did not affect the viability of either the bacteria or the A549 cells (data not shown). The concentration of S-CMC in the blood of healthy adults at 2 h after a single oral dose of 500 mg is ~5 μg ml⁻¹. Thirty years ago, a pharmacokinetic study showed that approximately 4 μg S-CMC ml⁻¹ could be detected in bronchial mucus samples collected from patients with acute exacerbations of chronic bronchitis at 2 h after a single oral dose of 2 g S-CMC-Lys, a lysine salt of S-CMC (Braga et al., 1982). Therefore, a level of S-CMC adequate to inhibit pneumococcal adherence on the surface of pharyngeal and alveolar epithelial cells can be expected following such administration.

The capsule is one of the most important pneumococcal virulence factors. Adamou et al. (1998) reported an isogenic acapsulated S. pneumoniae strain that adhered to a much greater extent than its encapsulated parental strain to bronchial epithelial cells. Hence, to examine the possibility that capsule production by tested isolates was attributable to differences in their ability to adhere to A549 cells and related to the inhibitory effects of S-CMC,

![Fig. 1. S-CMC inhibits pneumococcal adherence to human alveolar epithelial cells. A549 cells were treated with S-CMC at 37 °C for 30 min and then infected separately with S. pneumoniae serotype 6B strains P-03-90, P-03-160 or P-03-200, and serotype 19F strains P-03-11, P-03-99 or P-03-163, at an m.o.i. of 10 for 1 h. All experiments were performed three times with six technical repeats. Data are presented as means ± SD of six wells from a representative experiment. *, P<0.05.](http://jmm.sgmjournals.org)
capsule production by each strain was investigated (see Supplementary Fig. S1, available in JMM Online). Although strain P-03-99 had the lowest level of capsule production among the tested strains, it adhered efficiently to the epithelial cells in the absence of S-CMC. However, as no correlation between capsule production and the effect of S-CMC on pneumococcal adherence was observed, it is likely that interaction of the pneumococcal capsule with the host receptor is not affected by S-CMC.

S-CMC has been reported to reduce the number of exacerbations in COPD patients (Zheng et al., 2008). S. pneumoniae is frequently isolated from airway secretions of COPD patients during a period of exacerbation (Sethi & Murphy, 2001). To examine whether S-CMC inhibits pneumococcal adherence to chronically inflamed host cells, A549 cells stimulated with IL-1α were subjected to adherence assays. The serotype 6B strain P-03-200 and serotype 19F strain P-03-11, which were found to be similar in their level of capsule production, growth rate and adherence ability, were tested in the following experiments. Activation of A549 with IL-1α caused a fivefold increase in bacterial adherence to the cells in the absence of S-CMC (Fig. 2; compare with Fig. 1), which may have been caused by an increased expression of PAFR that occurs in cells stimulated with IL-1α (Cundell et al., 1995). Despite the increase in bacterial adherence to the cells, S-CMC efficiently reduced the enhanced adherence of both strains to the epithelial cells in a dose-dependent manner. These results suggest that the potency of S-CMC against S. pneumoniae adherence contributes to a reduction in COPD symptom exacerbation.

In rhinovirus infections, S-CMC reduces expression of the receptor intercellular adhesion molecule-1 (ICAM-1) and production of cytokines in human tracheal epithelial cells (Yasuda et al., 2006). Additionally, S-CMC reduces the concentration of IL-6 in the breath condensate of acute COPD patients (Caragnano et al., 2004). Based on findings showing that S-CMC possesses immunomodulatory properties, we speculated that S-CMC inhibits pneumococcal adherence as a result of downregulation of host receptor expression. The interaction of pneumococcal phosphorylcholine with PAFR is critical for the pathogenesis of pneumococcal infections; thus, we examined whether S-CMC repressed the gene expression of PAFR in A549 cells stimulated with IL-1α (Fig. 3a). Noticeable effects of S-CMC on the expression of PAFR at the transcriptional level were observed in A549 cells stimulated with IL-1α, whilst the amount of ICAM-1 mRNA in A549 cells was also reduced by S-CMC treatment. Non-typable H. influenzae is also an important pathogen of COPD exacerbation (Veeramachaneni & Sethi, 2006) and binds to a variety of host receptors, including PAFR and ICAM-1 (Swords et al., 2000, 2001; Avadhanula et al., 2006). It has been suggested that S-CMC-induced modulation of cell-surface charge contributes to a reduction in adherence of H. influenzae to epithelial cells. The results of our real-time PCR analysis raised the possibility that S-CMC could inhibit the adherence of H. influenzae to host epithelial cells by reducing the expression of PAFR and ICAM-1, thereby reducing exacerbation rates in COPD patients. The effects of S-CMC on the expression of PAFR in A549 cells stimulated with IL-1α were assessed by immunoblot analysis (Fig. 3b). Treatment of A549 cells with IL-1α enhanced the expression of PAFR in the absence of S-CMC. Although β-actin was not affected by treatment with S-CMC, PAFR expression was significantly inhibited by increased concentrations of S-CMC at the post-transcriptional level. Next, to examine whether S-CMC inhibited the interaction of S. pneumoniae and A549 cells stimulated with IL-1α, pneumococcal co-localization with PAFR was investigated using immunofluorescence microscopy (Fig. 3c). Adhered bacteria were observed on cells without
S-CMC treatment, some of which were co-localized with PAFR on epithelial cells. In contrast, there was a marked loss of fluorescence intensity for PAFR and adhered bacteria in S-CMC-treated cells. Furthermore, co-localization of bacteria with PAFR was scarcely observed in cells treated with S-CMC compared with non-treated cells. Taken together, our results demonstrated that S-CMC reduces the expression of PAFR, which in turn may inhibit the interaction of *S. pneumoniae* with host epithelial cells. To investigate further the mechanism by which S-CMC inhibits pneumococcal adherence via PAFR and phosphorylcholine, expression of PAFR was silenced by siRNAs, and PAFR was effectively knocked down by transfection of siRNAs into A549 cells (Fig. 4). The ability of *S. pneumoniae* to adhere to A549 cells transfected with PAFR siRNA was decreased compared with cells transfected with scrambled control oligonucleotides, indicating that PAFR is a major receptor on the surface of A549 cells for both *S. pneumoniae* strains. As expected, S-CMC inhibited the adherence of *S. pneumoniae* to A549 cells transfected with scrambled control oligonucleotides.

![Figure 3](http://jmm.sgmjournals.org)

**Fig. 3.** S-CMC reduces the expression of PAFR. (a) A549 cells were treated with S-CMC at 37°C for 30 min and then stimulated with 5 ng IL-1α ml⁻¹ for 4 h. cDNA was prepared from the cells and subjected to real-time RT-PCR analysis. The graph shows fold transcript level changes of PAFR, ICAM-1 and β-actin in cells treated with S-CMC (open bars) relative to non-treated cells (filled bars). Three independent experiments were performed and data are presented as means ± SD of six samples from a representative experiment. *, *P* < 0.01. (b) A549 cells were treated with S-CMC at 37°C for 30 min and then stimulated with 5 ng IL-1α ml⁻¹ for 4 h. PAFR expression was detected in whole-cell lysates by immunoblot analysis. β-Actin served as a loading control. The graph shows quantification of the PAFR bands shown in the blots. The intensity of the bands was digitized by Scion Image alpha 4.0.3.2 software (Scion) and normalized using that of β-actin, and representative results are presented as means ± SD of three independent experiments. Data are presented as fold expression levels relative to cells not treated with S-CMC and IL-1α. *, *P* < 0.05. (c) A549 cells were treated with S-CMC at 100 μg ml⁻¹ for 30 min and then stimulated with IL-1α at 5 ng ml⁻¹ for 30 min. Thereafter, the cells were infected separately with *S. pneumoniae* strain P-03-11 at an m.o.i. of 10 for 1 h. *S. pneumoniae* was visualized using an anti-capsule (serotype 19) and Alexa Fluor 488-conjugated antibodies. PAFR was stained with the anti-PAFR and Alexa Fluor 594-conjugated antibodies. DAPI was used to stain the DNA in the nucleus.
Although S-CMC unexpectedly inhibited pneumococcal adherence to A549 cells transfected with PAFR siRNA, this may have been due to the inhibitory effect of S-CMC on residual PAFR not knocked down in those cells. In addition, our findings raise the possibility that S-CMC represses several pneumococcal receptors, such as laminin receptor (Orihuela et al., 2009) and cytokeratin 10 (Shivshankar et al., 2009), on the surface of host cells in addition to PAFR.

Oxidative stress is an important feature in the pathogenesis of COPD. Increases in levels of reactive oxygen species have been implicated in initiating inflammatory responses in the lungs through activation of the transcriptional factor nuclear factor-κB (NF-κB) (Rahman, 2006). The production of IL-1α and tumour necrosis factor-α is also induced by NF-κB activation, which in turn facilitates PAFR expression (Mutoh et al., 1994). S-CMC-Lys has an antioxidant action that leads to a significant increase of glutathione (GSH) flux through the cell membrane (Guizzardi et al., 2006; Garavaglia et al., 2008). Such an increase in intracellular GSH induces a reduction in inflammatory cytokine release through inhibition of NF-κB activation (Aoki et al., 1996; Antonicelli et al., 2002; Biswas & Rahman, 2009). A previous study reported that the pyrrolidine derivative pyrrolidine dithiocarbamate, an NF-κB inhibitor, reduces acid-induced S. pneumoniae adherence to A549 cells via inhibition of PAFR induction (Ishizuka et al., 2001). Together, these findings suggest that the reduction in PAFR expression in epithelial cells treated with S-CMC is attributable to suppression of NF-κB activation by GSH flux. Polymeric immunoglobulin receptor (pIgR), a pneumococcal receptor of human epithelial cells, is also positively regulated by NF-κB (Bruno & Kaetzel, 2005). However, epithelial cells from the lower respiratory tract, such as A549 cells, express only traces of pIgR (Zhang et al., 2000). As pIgR is expressed in the upper respiratory tract at a high level, S-CMC may also have an effect on pneumococcal adherence via pIgR on the surface of these epithelial cells.

In M. catarrhalis infections, it has been demonstrated that decreased bacterial adherence in the presence of S-CMC is related to the ability of S-CMC to deplete the carbohydrate structure on the surface of pharyngeal epithelial cells (Zheng et al., 1999). Another study noted that S. pneumoniae probably recognizes a protein determinant irrespective of the presence or location of the carbohydrate on PAFR (García Rodríguez et al., 1995). Based on our results, we cannot exclude the possibility that S-CMC also affects the carbohydrate structure of PAFR.

The present results demonstrated that S-CMC inhibits S. pneumoniae adherence to alveolar epithelial cells via down-regulation of PAFR. As numerous respiratory pathogens, including Neisseria meningitidis and Pseudomonas aeruginosa, express phosphorylcholine on their surface to bind PAFR (Weiser et al., 1998), we speculate that S-CMC is extensively effective for respiratory tract infections caused by these pathogens.
In conclusion, to our knowledge this is the first report to show that S-CMC inhibits pneumococcal adherence to alveolar epithelial cells by reducing the expression of host receptors for S. pneumoniae, including PAFR. Our findings provide new insight into the underlying mechanism of the effectiveness of S-CMC for prevention of S. pneumoniae infection and may lead to novel therapeutic applications for respiratory infections.

ACKNOWLEDGEMENTS

We would like to thank Kyorin Pharmaceutical Co. Ltd, Japan, for financial support for this study. We thank K. Oishi for providing the S. pneumoniae strains and M. Higashino for helpful technical assistance. This work was supported by a grant-in-aid for Scientific Research on young scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (no. 20791336) awarded to T. S., a grant-in-aid for scientific research (B) from the Japan Society for the Promotion of Science (JSPS) (no. 20390465) awarded to S. K., a grant-in-aid for Scientific Research on young scientists (A) from MEXT (no. 2189048) awarded to Y. T. and a grant-in-aid for Scientific Research on young scientists (B) from MEXT (no. 19791343) awarded to M. N.

REFERENCES


